As we reflect on another year in the rare disease space, we are proud of the continued growth and evolution of CRA’s rare disease capabilities and offerings. Our rare disease consultants have undertaken more than 700 client projects over the past five years and nearly 150 in 2024 alone. These engagements have spanned a diverse range of therapeutic areas and modalities and drawn on our cross-functional expertise across strategy, policy, analytics, and litigation.
This year, we had the privilege of sharing our insights at global congresses, including the World Orphan Drug Congress and ISPOR, and contributing thought leadership articles on key challenges and opportunities in rare diseases.
This review highlights the breadth and depth of CRA’s activities in 2024. We look forward to continued collaboration as we navigate and shape the future of the rare disease space.
